A study by Columbia University's Mailman School of Public Health found that elderly women with localized breast cancer are less likely to receive chemotherapy, with only 15% receiving treatment. In contrast, younger women with nonmetastatic breast cancer received adjuvant chemotherapy at a rate of 70%.
A new study from the University of Michigan Comprehensive Cancer Center found that a single round of chemotherapy can identify patients most likely to benefit from preserving their speech. After three years, 78% of T4 study participants were still alive and 58% had an intact larynx.
Researchers design a minimally invasive system combining ultrasound and chemotherapy to target brain tumors without surgery or radiation. The approach aims to provide real-time imaging and localized temperature increases to melt liposome shells and release chemotherapy directly to the tumor.
Researchers found that adding gefinitib to standard chemotherapy improved tolerability in advanced head and neck cancer patients, but did not increase survival rates. The combination therapy showed potential in delaying the spread of the disease.
A new study by Memorial Sloan Kettering Cancer Center found that most patients with stage IV colorectal cancer do not require surgery to remove the primary tumor. Chemotherapy is an effective treatment option for these patients, allowing them to avoid surgical complications and start treatment sooner. The retrospective study analyzed 2...
A national survey reveals that nearly all oncologists and ID specialists are highly concerned about the negative impact of infection on treatment outcomes in chemotherapy patients. Infections among chemotherapy patients are common, with one in four patients experiencing an infection in the last 12 months.
A study found that 45% of older women with early-stage breast cancer choose chemotherapy, higher than the national average. The researchers suggest that these women are weighing risks and benefits more thoroughly, making informed decisions about their treatment.
A Phase II/III study found that ginger supplements, taken three days prior to and after chemotherapy, reduced nausea levels in cancer patients by 40%. The study included 644 participants who received at least three chemotherapy treatments and showed significant anti-vomiting effects.
A recent study found that chemotherapy in addition to surgery or radiation improves survival rates among older women with early-stage breast cancer. Combination therapy showed significantly better outcomes than single-drug treatment, with a 17% higher relapse-free survival rate at three years.
A Phase III trial found that adding casopitant mesylate to a conventional two-drug regimen significantly reduced chemotherapy-induced nausea and vomiting events. The study showed that 86% of patients achieved complete response with the new regimen compared to 66% with the placebo.
A phase III study found that adding cetuximab to standard chemotherapy for non-small-cell lung cancer (NSCLC) extends survival by almost one month compared to chemotherapy alone. The treatment has been shown to target epidermal growth factor receptor, which plays a key role in tumour growth.
A new combination of chemotherapy drugs, topotecan and docetaxel, has produced clinical benefit for patients with recurrent gynecologic cancers. The treatment showed an unusually high proportion of women experiencing clinical benefit, with a median survival time of 18.5 months.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a non-invasive method to determine whether chemotherapy is working after a single treatment cycle, allowing oncologists to discontinue ineffective treatments sooner. This breakthrough enables faster decision-making and potentially improves patient outcomes.
A new study by researchers at the University of Michigan Comprehensive Cancer Center found that higher doses of radiation combined with chemotherapy improve survival in patients with stage III lung cancer. Concurrent chemotherapy increases treatment effectiveness and overall survival rates.
A randomized controlled trial found that a 3-drug chemotherapy combination of docetaxel, cisplatin, and 5-fluorouracil (TPF) increased organ preservation rates in patients with locally advanced larynx cancer. Compared to the single-agent TPF, the addition of docetaxel improved larynx function and overall response rates.
A national study of over 700 patients will measure the cost and clinical effectiveness of acupressure wrist bands in reducing chemotherapy-related nausea. The device aims to provide a drug-free alternative for a debilitating symptom that affects quality of life, social life, and mental health.
A new test can predict which women with breast cancer are likely to respond to chemotherapy and which type of chemotherapy will work best for them. The test, known as the Breast Bioclassifier, has been validated on thousands of women and can help doctors prescribe targeted treatments that may not require chemotherapy.
A new genomic signature has been developed to predict how breast cancer patients respond to chemotherapy. The study found that the magnitude of the tumor's microenvironment, or reactive stroma, is predictive of a response to treatment. Patients with strong stroma reactions are more likely to have a bad response.
Researchers describe a technique to determine tumor blood vessel leakiness using digital mammography, allowing prediction of chemotherapy efficacy. The method is closely correlated with the ability of clinically approved chemotherapy agents to enter tumors.
A randomized controlled trial found that alternating cycles of chemotherapy and radiation have similar outcomes to sequential chemotherapy followed by radiation in treating larynx cancer. The study showed no significant difference in clinical outcomes between the two treatment groups.
A phase III trial found that palonosetron was non-inferior to granisetron in preventing acute nausea and vomiting but more effective in the delayed phase, offering a safer alternative for chemotherapy prevention.
A study published by researchers at M.D. Anderson Cancer Center revealed that intense chemotherapy significantly reduces the risk of recurrence in young mantle cell lymphoma patients. In a median follow-up of seven years, 52% of patients aged 65 or younger achieved disease-free survival.
A new study from Michigan Medicine found that a commonly used tool for estimating breast cancer recurrence risk is not effective at explaining risk to patients. Women with early-stage breast cancer may struggle to understand the benefits and risks of chemotherapy, leading to poor treatment choices.
A phase III, international randomized clinical trial supports a new standard of treatment for women with advanced ovarian cancer, reducing complications and post-operative deaths. The study demonstrates that neoadjuvant chemotherapy followed by interval debulking surgery can be the preferred treatment for patients with very extensive d...
The Novo-TTF device was shown to enhance the efficacy of standard chemotherapy in treating newly-diagnosed glioblastoma multiforme patients. Combination therapy with the device prolonged time to disease progression by nearly 31 months and increased survival by more than 25 months compared to historical results.
A study found that patients with locally advanced lung cancer who received proton therapy and chemotherapy had fewer instances of bone marrow toxicity compared to those receiving IMRT and chemotherapy. This suggests that proton therapy may be a more effective option for treating this serious side effect, enabling doctors to give higher...
Researchers found that proton therapy with concurrent chemotherapy significantly reduced bone marrow toxicity in patients with locally advanced non-small cell lung cancer, improving treatment efficacy and patient outcomes. The study suggests proton therapy as a safer option for vulnerable patients, including children and the elderly.
A multi-center phase II clinical trial found improved survival in patients with advanced non-small cell lung cancer treated with chemotherapy and targeted therapies bevacizumab and cetuximab. The combination showed no safety concerns, indicating a potential future treatment option for lung cancer.
A new study published in the Proceedings of the National Academy of Sciences found that apigenin, a naturally occurring compound in fruits and vegetables, improves cancer cells' response to chemotherapy. By localizing tumor suppressor p53 in the cell nucleus, apigenin facilitates cell death and stops tumor growth.
A new study reveals that poorer socioeconomic status increases mortality risk in non-Hodgkin lymphoma patients, while chemotherapy reduces the risk. Ethnic disparities are also observed, with African-Americans less likely to receive chemotherapy and living in poorer communities.
A University of Cincinnati study finds that bisphenol A (BPA) induces proteins protecting cancer cells from chemotherapy's toxic effects. Researchers suggest BPA may be a contributing factor to chemotherapy resistance in cancer patients.
A retrospective study found that women with 3 or fewer involved lymph nodes have a low relapse rate after undergoing pre-operative chemotherapy and mastectomy. Patients with zero involved lymph nodes had a zero percent recurrence rate.
Researchers found that anti-angiogenic drugs block chemotherapy-induced blood vessel formation, thereby hindering tumor regrowth. This mechanism may explain why some chemotherapy combinations enhance treatment efficacy.
Researchers discovered that injections of N-acetyl cysteine (NAC) can prevent memory loss induced by breast cancer chemotherapy drugs. The study, published in the Springer journal Metabolic Brain Disease, suggests a potential remedy for chemobrain symptoms, which affect up to 40% of cancer patients undergoing chemotherapy.
Researchers found that mitochondrial cholesterol increases resistance to chemotherapy in liver cancer. Statins could potentially sensitise cancer cells against chemotherapy by reducing mitochondrial cholesterol levels.
A new study from Duke University Medical Center found that changes in doctors' reimbursement for chemotherapy treatments did not affect patients' access to care. The study measured patient access by looking at distance traveled and time between diagnosis and initiation of chemotherapy.
New research indicates that the Medicare Modernization Act of 2003 has not led to significant changes in patient wait times or travel distance for chemotherapy treatment. The study found that the number of patients traveling farther for chemotherapy remained stable after 2003, with no major increases in wait times.
Researchers at UC San Diego develop a nanoscale drug delivery system targeting integrin ανβ3 protein on tumor blood vessels, reducing collateral damage. The approach shows promise in treating metastatic disease with lower chemotherapy doses.
Researchers at McGill University have discovered a compound called silvestrol that can re-sensitize tumors to chemotherapy, making them susceptible to anticancer drugs. Silvestrol, derived from Malaysian folk medicine, has been shown to effectively reduce resistance to chemotherapy agents used to treat cancer.
A pilot study at Duke University Medical Center found that disabling a protein on melanoma cells makes them more vulnerable to chemotherapy, resulting in complete responses in 8 out of 16 patients. The compound ADH-1 was tested in combination with chemotherapy and showed promising results.
A new study suggests that targeting and disabling a protein in melanoma tumors can make them more vulnerable to chemotherapy. Researchers found that combining targeted therapy with melphalan chemotherapy reduced tumor size by up to 30-fold, compared to chemotherapy alone.
Researchers conclude that adding chemotherapy to active symptom control does not improve overall survival or quality of life for mesothelioma patients. However, exploratory analyses suggest that vinorelbine may merit further investigation.
A new study from the University of Michigan Comprehensive Cancer Center found that black patients are 23% less likely to receive chemotherapy and 12% less likely to receive radiation therapy for rectal cancer compared to white patients. Despite similar rates of consultation with oncologists, disparities in treatment initiation persist.
A new treatment combination using a genetically altered herpes virus and chemotherapy drug reduces tumor size in mice with aggressive human sarcoma. The therapy appears to be well-tolerated, but further development is needed before clinical trials can begin.
A recent study found that women with BRCA2-associated breast cancer had a higher response rate and longer overall survival when treated with anthracycline-based regimens. Researchers believe this may be due to the lack of functional BRCA1/2 proteins, which impair DNA repair after chemotherapy.
Two studies suggest that chemotherapy is not the cause of memory problems in breast cancer patients, but rather stress and quality of life factors. Women with recent diagnoses performed similarly on cognitive tests to those without cancer, while those who had completed treatment showed better scores.
Researchers at UAB have discovered that triphendiol induces cell death in pancreatic and bile duct cancer cells, slowing tumor growth and sensitizing tumors to chemotherapy treatments. The investigational drug has shown promise as a potential treatment for pancreatic adenocarcinoma.
The Novo-TTF device demonstrated significant efficacy in reducing tumor volume and improving outcomes for patients with locally advanced breast cancer. The device's non-invasive technology disrupts cancer cell proliferation, offering a potential alternative to traditional chemotherapy.
A randomized controlled trial found that high-dose chemotherapy did not increase survival rates for patients with small cell lung cancer. Despite increased tumor shrinkage, the high-intensity approach was deemed ineffective and highly toxic.
Patients with breast cancer who developed anemia during chemotherapy had a significantly higher risk of local recurrence compared to those without anemia. Anemia was defined as a serum hemoglobin level below 12 g/dL during chemotherapy, and occurred in 18.2% of patients receiving CMF chemotherapy.
Researchers at USC have found that fasting for two days protects healthy cells from chemotherapy, while leaving cancer cells vulnerable. This discovery holds promise for developing more selective and less toxic chemotherapy treatments.
The EORTC Intergroup trial found that chemotherapy plus surgery on liver tumors improved progression-free survival by 26% in patients with colorectal cancer. Patients who received chemotherapy before and after surgery had a higher rate of progression-free survival compared to those who underwent surgery alone.
A randomized clinical trial found that postoperative chemotherapy does not improve survival in patients with localized gastric cancer. Despite promising results in advanced gastric cancer, the combination of cisplatin, epirubicin, and other chemotherapies did not show significant benefits.
Researchers identify nerve that transmits signals of chemotherapy-associated illness from small intestine to brain, offering new approach to reduce debilitating side effects. Anorexia and cachexia often accompany chemotherapy symptoms, compromising patient's nutritional status.
Researchers found Ki-67 expression associated with poorer disease-free survival, but not predictive of chemotherapy benefit. Pathology reports offer a reliable alternative for determining ER status in breast cancer trials.
A study published in the World Journal of Gastroenterology found that Fu-Zheng-Jie-Du-Decoction increased PTEN expression in hepatocellular carcinoma, suggesting a promising future for TCM as a combined therapy. The decoction was shown to decrease tumor metastasis and improve survival rates compared to chemotherapy.
A randomized clinical trial found that adding docetaxel to anthracycline-based chemotherapy improved disease-free survival in breast cancer patients. The study showed a 4% increase in five-year disease-free survival rates, with patients receiving sequential docetaxel after doxorubicin having the best outcomes.
Research from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) found that chemotherapy safely reduced recurrence, breast cancer mortality, and death from any cause in women with hormone-resistant breast cancer. The study showed a 10-year risk reduction of 25% in younger women and 39% in women aged 50-69 years.
A large clinical trial found that bevacizumab significantly prolongs progression-free survival for women with recurrent breast cancer when combined with chemotherapy. The study showed a doubling of delay in worsening of the disease and improved remission rates compared to chemotherapy alone.
Breast cancer patients who received tamoxifen or chemotherapy had a reduced risk of developing a second cancer in the other breast. Chemotherapy was associated with a 43% risk reduction, lasting up to 10 years, while tamoxifen use resulted in a 34% risk reduction that persisted for five years.